Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
About this trial
Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.
Eligibility criteria
Qualifiers
patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity <10% with anti-ADAMTS13 antibodies detected);
aged ≥ 18 years;
male and female patients;
treated with daratumumab for iTTP.
Disqualifiers
patients unwilling or unable to provide their informed consent;
follow-up < 6 months after daratumumab administration.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
40 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov